Resources

Selected
  • 国电电力 2025年光伏毛利率
Type of publications
Regions
Diseases
273 results found
2025 ∙ Sun, J. Dong, S. Gong, J. Xie, J. Yan, H.
Human papillomavirus vaccination willingness and influencing factors among women in China: A systematic review and meta-analysis
Western Pacific China Children Adolescents Adults Human papillomavirus (HPV) Acceptance
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ la Cruz, R. A. R. D. Flores-Cordova, J. M. Calderon-Hernandez, C. C. Cahuapaza-Gutierrez, N. L. Ccallalli-Ruiz, N. A. Runzer-Colmenares, F. M.
Humoral and Cellular Immune Responses Against SARS-CoV-2 Following COVID-19 Vaccination in Older Adults: A Systematic Review
Adults Older adults COVID-19 Administration Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2025 ∙ Martinez-Serrano, A. Pulido-Fuentes, M. Notario-Pacheco, B. Palmar-Santos, A. M. Cobo-Cuenca, A. I. Diez-Fernandez, A.
Immunity Awareness-Strategies to Improve the Degree of Acceptance of Vaccines: A Systematic Review
All age groups Healthcare workers Parents/caregivers
Methodological quality (AMSTAR 2):
Not applicable
2025 ∙ Niyati, R. Rezahosseini, O. Ekenberg, C. Larsen, C. S. Harboe, Z. B.
Immunogenicity and Safety of Pneumococcal Vaccines Co-Administered with Common Travel Vaccines in Adults: A Systematic Review +
Adults Older adults Pneumococcal disease Efficacy/effectiveness Safety Administration
Methodological quality (AMSTAR 2):
Low
2025 ∙ Chen, Z. Wan, C. Chen, B. Mo, Q. Ju, M. Deng, K. Li, X. Qin, D.
Immunogenicity and safety of the booster COVID-19 vaccine among people with HIV: a systematic review and meta-analysis
All age groups COVID-19 Efficacy/effectiveness Safety Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Yuan, Y. Wang, T. Xia, Y. Shi, Z. He, P.
Immunogenicity and safety of the domestic and imported live-attenuated varicella vaccine in healthy Chinese populations: a systematic review and meta-analysis
Western Pacific China Newborn Children Adolescents Adults Varicella Efficacy/effectiveness Safety
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Ngamprasertchai, T. Ruenroengbun, N. Kajeekul, R.
Immunogenicity and Safety of the Higher-Valent Pneumococcal Conjugate Vaccine vs the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Adults Older adults Pneumococcal disease Efficacy/effectiveness Safety Administration
Methodological quality (AMSTAR 2):
Low
2025 ∙ Martins, A. M. Valero Juan, L. F. Santos, M. Martins, J. P.
Immunogenicity as a Predictor of Influenza Vaccine Efficacy: A Systematic Review
Children Adolescents Adults Older adults Influenza Efficacy/effectiveness Modeling
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Davis, P. Montroy, J. Warshawsky, B. Abrams, E. M. Coward, L. Killikelly, A.
Immunogenicity of pre-exposure rabies vaccination comparing number of doses and routes of administration: A systematic review and meta-analyses
All age groups Rabies Efficacy/effectiveness Administration
Methodological quality (AMSTAR 2):
Critically low
2025 ∙ Ul Haq, M. Z. Irfan, H. Shah, M. S. U. Sumbal, A. Mughal, S. Ashraf, S. Basaria, A. A. A. Abdullah, Chacho, M. A. Ayalew, B. D.
Immunogenicity, safety and tolerability of 15-valent pneumococcal conjugate vaccine (V114) compared to 13-valent pneumococcal conjugate vaccine (PCV-13) in healthy infants: A systematic review and meta-analysis
Newborn Pneumococcal disease Efficacy/effectiveness Safety Administration
Methodological quality (AMSTAR 2):
Low
Loading...